NASDAQ:CGEN - Compugen Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.3750 -0.12 (-3.43 %) (As of 07/22/2018 04:00 PM ET)Previous Close$3.3750Today's Range$3.35 - $3.5152-Week Range$2.25 - $5.00Volume73,443 shsAverage Volume248,893 shsMarket Capitalization$173.11 millionP/E RatioN/ADividend YieldN/ABeta0.26 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Receive CGEN News and Ratings via Email Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:CGEN CUSIPN/A Webwww.cgen.com Phone972-3765-8585 Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$710,000.00 Price / Sales243.81 Cash FlowN/A Price / CashN/A Book Value$0.57 per share Price / Book5.92 Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-37,060,000.00 Net MarginsN/A Return on Equity-78.00% Return on Assets-62.61% Miscellaneous Employees101 Outstanding Shares51,290,000Market Cap$173.11 Compugen (NASDAQ:CGEN) Frequently Asked Questions What is Compugen's stock symbol? Compugen trades on the NASDAQ under the ticker symbol "CGEN." How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.04. The biotechnology company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.11 million. View Compugen's Earnings History. When is Compugen's next earnings date? Compugen is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Compugen. What price target have analysts set for CGEN? 2 brokerages have issued 12-month price targets for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Compugen's share price to reach $9.00 in the next year. This suggests a possible upside of 166.7% from the stock's current price. View Analyst Ratings for Compugen. What is the consensus analysts' recommendation for Compugen? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Compugen's key competitors? Some companies that are related to Compugen include CASI Pharmaceuticals (CASI), Mesoblast (MESO), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), Nightstar Therapeutics (NITE), Novavax (NVAX), Vericel (VCEL), PDL BioPharma (PDLI), Scholar Rock (SRRK), Cellular Biomedicine Group (CBMG), Surface Oncology (SURF), Osiris Therapeutics (OSIR), Adverum Biotechnologies (ADVM) and NanoString Technologies (NSTG). Who are Compugen's key executives? Compugen's management team includes the folowing people: Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)Dr. John J. Hunter, VP of Antibody R&D (Age 55) Has Compugen been receiving favorable news coverage? News stories about CGEN stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Compugen earned a media sentiment score of 0.14 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are Compugen's major shareholders? Compugen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Benjamin F. Edwards & Company Inc. (0.33%). View Institutional Ownership Trends for Compugen. Which major investors are buying Compugen stock? CGEN stock was acquired by a variety of institutional investors in the last quarter, including Benjamin F. Edwards & Company Inc.. View Insider Buying and Selling for Compugen. How do I buy shares of Compugen? Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Compugen's stock price today? One share of CGEN stock can currently be purchased for approximately $3.3750. How big of a company is Compugen? Compugen has a market capitalization of $173.11 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe. How can I contact Compugen? Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected] MarketBeat Community Rating for Compugen (NASDAQ CGEN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 197 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 373MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?